These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36960055)

  • 1. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
    Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
    Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
    Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
    Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential polarization and the expression of efferocytosis receptor MerTK on M1 and M2 macrophages isolated from coronary artery disease patients.
    Mohd Idrus FN; Ahmad NS; Hoe CH; Azlan M; Norfuad FA; Yusof Z; Wan Isa WYH; Mohamed Ali AA; Yvonne-Tee GB
    BMC Immunol; 2021 Mar; 22(1):21. PubMed ID: 33761885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-based modulation of macrophage-mediated efferocytosis potentiates antitumor immunity in colorectal cancer.
    Zhou X; Li D; Xia S; Ma X; Li R; Mu Y; Liu Z; Zhang L; Zhou Q; Zhuo W; Ding K; Lin A; Liu W; Liu X; Zhou T
    J Control Release; 2024 Feb; 366():128-141. PubMed ID: 38104775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
    Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
    Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
    Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidoglycan from Bacillus anthracis Inhibits Human Macrophage Efferocytosis in Part by Reducing Cell Surface Expression of MERTK and TIM-3.
    Mytych JS; Pan Z; Lopez-Davis C; Redinger N; Lawrence C; Ziegler J; Popescu NI; James JA; Farris AD
    Immunohorizons; 2024 Mar; 8(3):269-280. PubMed ID: 38517345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
    Myers KV; Amend SR; Pienta KJ
    Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
    Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
    Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation.
    Nishi C; Yanagihashi Y; Segawa K; Nagata S
    J Biol Chem; 2019 May; 294(18):7221-7230. PubMed ID: 30846565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury.
    Soliman E; Leonard J; Basso EKG; Gershenson I; Ju J; Mills J; de Jager C; Kaloss AM; Elhassanny M; Pereira D; Chen M; Wang X; Theus MH
    J Neuroinflammation; 2023 Nov; 20(1):256. PubMed ID: 37941008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tim-3 facilitates immune escape in benzene-induced acute myeloid leukemia mouse model by promoting macrophage M2 polarization.
    Ning Q; Jian T; Cui S; Shi L; Jian X; He X; Zhang X; Li X
    Ecotoxicol Environ Saf; 2023 Nov; 266():115532. PubMed ID: 37806131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
    Chen R; Huang B; Lian M; Wei Y; Miao Q; Liang J; Ou Y; Liang X; Zhang H; Li Y; Xiao X; Wang Q; You Z; Chai J; Gershwin ME; Tang R; Ma X
    J Hepatol; 2023 Dec; 79(6):1478-1490. PubMed ID: 37659731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
    Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB
    J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of macrophage MERTK exhibits profibrotic effects and results in defective regulation of efferocytosis function in pulmonary fibrosis.
    She Y; Xu X; Yu Q; Yang X; He J; Tang XX
    Respir Res; 2023 Apr; 24(1):118. PubMed ID: 37120511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Cross-Linking of CD14 Activates MerTK and Promotes Human Macrophage Clearance of Apoptotic Neutrophils: the Dual Role of CD14 at the Crossroads Between M1 and M2c Polarization.
    Zizzo G; Cohen PL
    Inflammation; 2018 Dec; 41(6):2206-2221. PubMed ID: 30091033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L2
    Tavukcuoglu E; Horzum U; Yilmaz KB; Esendagli G
    Immunol Cell Biol; 2020 Feb; 98(2):152-164. PubMed ID: 31845380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mertk Interacts with Tim-4 to Enhance Tim-4-Mediated Efferocytosis.
    Moon B; Lee J; Lee SA; Min C; Moon H; Kim D; Yang S; Moon H; Jeon J; Joo YE; Park D
    Cells; 2020 Jul; 9(7):. PubMed ID: 32640697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.
    Bae SH; Kim JH; Park TH; Lee K; Lee BI; Jang H
    Exp Mol Med; 2022 Sep; 54(9):1450-1460. PubMed ID: 36056187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mertk: An emerging target in cancer biology and immuno-oncology.
    Lahey KC; Gadiyar V; Hill A; Desind S; Wang Z; Davra V; Patel R; Zaman A; Calianese D; Birge RB
    Int Rev Cell Mol Biol; 2022; 368():35-59. PubMed ID: 35636929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.